$ 584.74
Key Takeaways
Risk factor
Strong trading liquidity
Profitability factor
Very strong margins and returns
About
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,
Target Price
The average target price of REGN is 698 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
